ALEMTUZUMAB

Alemtuzumab was initially developed during the 1980s at the University of Cambridge. It originated as a laboratory antibody called Campath-1, which was later humanised to develop Alemtuzumab. The medicine works by targeting CD52, a protein present on the surface of specific immune cells, helping regulate excessive immune system activity. It was initially used to treat B-cell chronic lymphocytic leukaemia (CLL) and was later found to be beneficial in autoimmune disorders such as multiple sclerosis (MS). Alemtuzumab received its first approval from the U.S. FDA in May 2001 through an accelerated approval pathway for patients with refractory B-cell chronic lymphocytic leukaemia (CLL). It subsequently gained full FDA approval in September 2007 for broader treatment of CLL. Later, Alemtuzumab was approved in the European Union in September 2013 for relapsing-remitting multiple sclerosis (RRMS), followed by U.S. FDA approval on November 14, 2014, for patients who had an inadequate response to other MS therapies.

Alemtuzumab is used in the treatment of the following: Relapsing-Remitting Multiple Sclerosis (RRMS) Chronic Lymphocytic Leukaemia (CLL) Pre-transplant Conditioning (off-label use)

Common (usually mild and temporary): Headache Fever or chills Nausea and vomiting Rash or itching Tiredness or weakness Back pain or joint pain Difficulty sleeping Mouth or throat pain Cough or shortness of breath Low white blood cell counts (may increase infection risk) Serious (less common, seek medical help): Severe infections (e.g., pneumonia, urinary tract infections, viral reactivation) Autoimmune reactions (e.g., thyroid disorders, kidney problems) Infusion-related reactions (chest pain, drop in blood pressure, breathing difficulty) Liver problems (yellowing of skin or eyes, dark urine) Bleeding or bruising easily (due to low platelets) Neurological issues (confusion, vision changes, weakness in limbs) Risk of certain cancers (rare but possible with long-term use) Most people tolerate the medicine well, but any unexpected or worsening symptoms should be reported right away.

Alemtuzumab can cause permanent hearing damage, especially with high doses or long use. Report any ringing in your ears or changes in your hearing to your healthcare provider immediately. It may lead to kidney problems. Regular monitoring of kidney function is needed during treatment. Alemtuzumab can sometimes cause nerve damage, leading to muscle weakness or numbness, especially in high doses. Elderly people are at higher risk of side effects like hearing or kidney damage and need careful monitoring. Alemtuzumab may harm the unborn baby and should only be used in pregnancy if absolutely necessary and prescribed by a doctor.

Contraception is essential – Use effective birth control during treatment and for 4 months after the last dose, as the drug may harm an unborn baby. Avoid live vaccines – Your immune system may be suppressed, and vaccines may not work properly or may cause infections. Routine monitoring required – Regular blood and urine tests are needed for up to 4 years to detect delayed side effects like autoimmune disorders. Inform about all medications – Let your doctor know about all medicines, including supplements and herbal products, to avoid harmful interactions. Discuss medical history – Tell your doctor if you have liver disease, thyroid problems, bleeding disorders, or a history of infections.

U.S. Full Prescribing Information for Campath (alemtuzumab) https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/lemtrada-alemtuzumab.pdf Randomised Trials vs. Interferon Beta‑1a in RRMS — Major clinical studies showing that alemtuzumab was more effective than interferon beta‑1a in reducing relapses and disability progression https://www.nejm.org/doi/full/10.1056/NEJMoa0802670 Alemtuzumab in Relapsing‑Remitting MS: Efficacy & Long‑term Safety Reviews — Cochrane and longitudinal data confirming durable benefits with close monitoring of safety over extended follow‑up https://journals.sagepub.com/doi/full/10.1177/17562864231194823 Real‑World Practice Evidence — Observational studies confirming high real-world effectiveness and expected safety profiles consistent with clinical trials https://www.sciencedirect.com/science/article/abs/pii/S221103482300264X